Business Context and Reporting Period
Company: Grifols, S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Six months ended June 30, 2025 (H1 2025)
Filing Date: July 30, 2025
Overview: Grifols is a global healthcare company and leader in plasma-derived medicines. The period reflects the execution of the company's "Value Creation Plan," characterized by commercial growth, margin expansion, and deleveraging.
Key Financial Metrics
| Metric | H1 2025 | H1 2024 | Change (Constant Currency) |
|---|---|---|---|
| Revenue | EUR 3,677 million | EUR 3,444 million | +7.0% |
| Adjusted EBITDA | EUR 876 million | EUR 791 million | +12.7% |
| Adjusted EBITDA Margin | 23.8% | 23.0% | +80 bps |
| Group Net Profit | EUR 177 million | EUR 36 million | +387.6% |
| Free Cash Flow (pre-M&A) | EUR -14 million | EUR -196 million | Improvement of EUR 182 million |
| Leverage Ratio | 4.2x | 5.5x | -1.3x |
| Liquidity | EUR 1.4 billion | N/A | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by the Biopharma segment, which grew 8.2% at constant currency (cc). Immunoglobulin (IG) revenues rose 12.5% cc, with subcutaneous IG (SCIG) growing 66% cc. Diagnostic revenues increased 2.8% cc.
- Profitability Surge: Group net profit increased nearly four-fold to EUR 177 million, driven by EBITDA growth, working capital management, and reduced interest costs.
- Deleveraging: The leverage ratio improved significantly from 5.5x in H1 2024 to 4.2x in H1 2025.
- Corporate Actions:
- Completed the delisting of Biotest AG from the Frankfurt Stock Exchange, increasing equity stake to 80.32% (cost: EUR 108 million).
- Reinstated a dividend payment of EUR 0.15 per share, the first since June 2021.
- Acquired remaining plasma centers from Immunotek (Groups 3 & 4), gaining full control of 28 U.S. centers.
Guidance, Outlook, and Risks
- 2025 Guidance: Reaffirmed overall guidance. Improved Free Cash Flow (pre-M&A) guidance to EUR 375-425 million.
- FX Impact: Recent depreciation of the U.S. dollar is expected to be a headwind to reported Revenue and EBITDA in H2 2025, but the impact on Group Profit, leverage, and FCF is expected to be broadly neutral due to underlying momentum and cost levers.
- Pipeline Milestones: On track to launch Fibrinogen in Europe in Q4 2025 and in the U.S. in H1 2026 following FDA approval.
- Risks:
- Regulatory/Tariffs: Potential U.S. tariffs and regulatory changes (e.g., One Big Beautiful Bill Act). Management believes the vertically integrated model mitigates these risks.
- Taxation: Ongoing tax audits in Spain and the U.S. (IRS transfer pricing review). A net provision of EUR 21.1 million was recorded for uncertain tax treatments.
Investor Verification Checklist
- FCF Sustainability: Verify the trajectory of Free Cash Flow generation to ensure the improved guidance of EUR 375-425 million is achievable given the negative H1 result.
- Biotest Integration: Assess the financial impact and synergies of the increased 80.32% stake in Biotest following the delisting.
- FX Sensitivity: Monitor the impact of USD/EUR exchange rate fluctuations on H2 2025 reported revenue and EBITDA.
- Dividend Policy: Confirm the sustainability of the reinstated dividend (EUR 0.15/share) against future cash flow projections.
- Regulatory Approvals: Track the FDA approval timeline for Fibrinogen to ensure the H1 2026 U.S. launch target remains on schedule.